Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Mol Hepatol. 2013 Mar;19(1):82-6. doi: 10.3350/cmh.2013.19.1.82. Epub 2013 Mar 25.

Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B.

Author information

1
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Abstract

Telbivudine is an L-nucleoside analogue with potent antiviral activity against hepatitis B virus (HBV). Clinical trials have shown that telbivudine has a more potent and sustained antiviral activity with a lower frequency of viral resistance than lamivudine. Although there are several reports concerning the safety profile of telbivudine, most adverse events are described as mild and transient in nature. Here we report two cases of telbivudine-induced myopathy in patients with chronic hepatitis B who were siblings.

KEYWORDS:

Adverse effects; Hepatitis B; Myopathy; Telbivudine

PMID:
23593614
PMCID:
PMC3622860
DOI:
10.3350/cmh.2013.19.1.82
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for The Korean Association for the Study of the Liver Icon for PubMed Central
    Loading ...
    Support Center